Aseptix signs global technology license with Ecolab

Loenen aan de Vecht, December 15, 2014 - minute read

Aseptix Health Sciences NV, the specialist in next generation antimicrobials headquartered in the Netherlands, today announced a global license agreement with Ecolab. Under the agreement, Ecolab will acquire a global license for Professional Markets on Aseptix technologies and acquire the Professional Products Division of Aseptix. Aseptix currently sells its Aseptix-branded professional products in Europe and India, mainly to healthcare, food processing and pharmaceutical clients.

Aseptix is the inventor of activated hydrogen peroxide technologies, a fast-acting and user-safe technology to effectively eradicate numerous pathogens with outstanding material compatibility and without burdening residues. The active ingredient degrades to water and oxygen after use.

Under this transaction, Aseptix will continue to own the intellectual property of more than 60 patents around its technologies and related know-how, while Ecolab will receive exclusive rights for use of the majority of Aseptix’s technologies in professional markets around the world. This enables Aseptix to stay independent and capitalize on its proven technologies for consumer applications across many markets globally.

The agreement with Ecolab fits the Aseptix strategy of globalizing the technology and creating the new global standard in infection prevention. With the growth in hospital acquired infections (HAI) and increasing focus on clean environments, the relevance of these types of solutions is rapidly increasing.

It is Aseptix’ ambition to offer state of the art products in the fight against dangerous microbes. The Aseptix technology is unique, since it offers broad efficacy spectrum and short contact times, is safer for people and environment and is very easy to use.

Ilja Bobbert, founder and CEO of Aseptix: “This is a major milestone for Aseptix. Aseptix has laid the initial groundwork and has proven the products can lower infection rates in many industries. Now, Ecolab can truly globalize the technology across their business segments, and geographies worldwide.”

 For many years, Aseptix is a trusted partner with a proven track record in building long lasting and profitable partnerships with market leaders in various industries across the globe. The company’s objective is to exploit Aseptix’s safe and environmentally friendly technologies in numerous antimicrobial applications globally. With this transaction aimed at the professional markets, Aseptix can improve its company efforts on licensing the technologies to household care and personal care applications.


About Aseptix

Aseptix Health Sciences NV, is a leading global innovator of next generation, proprietary antimicrobial products and technologies for professional and consumer use. Its antimicrobial technologies enable products to safely, effectively and quickly eradicate contagious pathogens and are used in a wide range of applications, industries and therapeutic areas. Example clients of Aseptix are: The Clorox Company, SCA (Tork), Initial, Reckitt Benckiser (Scholl), and many others. The Company markets its products and technologies through a combination of Aseptix branded and third-party branded antimicrobial end-products, and licenses on its portfolio of technologies to global industry leaders. Aseptix owns more than 60 global patents.

For more information, visit

About Ecolab

A trusted partner at more than one million customer locations, Ecolab (ECL) is the global leader in water, hygiene and energy technologies and services that protect people and vital resources. With 2013 sales of $13 billion and 45,000 associates, Ecolab delivers comprehensive solutions and on-site service to promote safe food, maintain clean environments, optimize water and energy use and improve operational efficiencies for customers in the food, healthcare, energy, hospitality and industrial markets in more than 170 countries around the world. For more Ecolab news and information, visit

Back to articles